New hope for lung cancer patients with brain tumors: drug duo enters trial
Disease control
Not yet recruiting
This phase 2 trial tests a combination of two drugs, Sacituzumab tirumotecan and bevacizumab, in 50 people with a specific type of lung cancer (EGFR-mutant nonsquamous NSCLC) that has spread to the brain and no longer responds to standard targeted therapy. The goal is to see if t…
Phase: PHASE2 • Sponsor: Li-kun Chen • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC